MLTX — MoonLake Immunotherapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $2.53bn
- $2.09bn
- 35
- 22
- 28
- 18
Annual balance sheet for MoonLake Immunotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS/A | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Cash | ||||
| Cash and Equivalents | ||||
| Short Term Investments | ||||
| Cash and Short Term Investments | 8.04 | 72.1 | 511 | 448 |
| Net Total Receivables | 1.43 | 4.18 | 3.05 | 25.8 |
| Prepaid Expenses | ||||
| Total Current Assets | 9.64 | 76.5 | 514 | 474 |
| Net Property, Plant And Equipment | 0.046 | 0.332 | 3.95 | 3.64 |
| Other Long Term Assets | ||||
| Total Assets | 9.68 | 76.8 | 527 | 478 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 21.1 | 7.67 | 9.97 | 22.5 |
| Total Long Term Debt | ||||
| Total Debt | ||||
| Minority Interest | ||||
| Total Other Liabilities | ||||
| Total Funded Status | ||||
| Total Liabilities | 21.3 | 27.9 | 30.9 | 31.1 |
| Non Redeemable Preferred Stock | ||||
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Treasury Stock | ||||
| Other Equity | ||||
| Total Equity | -11.6 | 48.9 | 496 | 447 |
| Total Liabilities & Shareholders' Equity | 9.68 | 76.8 | 527 | 478 |
| Total Common Shares Outstanding |